JTE-522

JTE-522 is a selective cyclooxygenase-2 (COX-2) inhibitor that was developed by Japan Tobacco. Chemically identified as 4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide, it is a small molecule designed to block the synthesis of prostaglandin E2 (PGE2), a key mediator in inflammation and carcinogenesis that is frequently overexpressed in various tumors. Preclinical research has investigated JTE-522 for its potential chemotherapeutic and chemopreventive effects in esophageal and bladder cancers. In esophageal cancer models, it has demonstrated the ability to reduce tumor formation and suppress developing carcinomas. In bladder cancer studies, JTE-522 has shown synergistic cytotoxic and apoptotic effects when combined with cisplatin (CDDP), potentially by downregulating anti-apoptotic molecules like Bcl-2. Despite these promising preclinical findings, the development of JTE-522 was not continued to clinical approval.

Other names

4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide